Literature DB >> 24029945

Injury models to study cardiac remodeling in the mouse: myocardial infarction and ischemia-reperfusion.

Daniel J Luther1, Charles K Thodeti, J Gary Meszaros.   

Abstract

Deep tissue wound healing requires a complex sequence of several factors working in unison to repair the organ at risk. Myocardial infarction (MI) is particularly complex due to several local and systemic factors mediating the repair process within the heart. The wound healing process during this time is critical-the cardiac myocytes are at risk of apoptotic cell death, autophagy, and necrosis. During the early remodeling period, the fibroblasts and myofibroblasts play critical roles in infarct scar formation, a process that is greatly influenced by a robust inflammatory response. Construction of the infarct scar is a "necessary evil" that helps to limit expansion of the infarction; however, the collagen and matrix deposition will often spread to the healthy areas of the heart, causing reactive fibrosis in areas remote from the original damage. This chapter outlines in detail the procedures for two myocardial infarction injury models as well as how to quantify the size of the experimentally induced injury. These procedures are critical to the development of in vivo approaches to study myocardial injury, particularly for use in knockout and transgenic mice.

Entities:  

Mesh:

Year:  2013        PMID: 24029945     DOI: 10.1007/978-1-62703-505-7_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Transplantation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Mouse Myocardial Infarction Model.

Authors:  Takeshi Hatani; Yoshinori Yoshida
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Considerations to Model Heart Disease in Women with Preeclampsia and Cardiovascular Disease.

Authors:  Clara Liu Chung Ming; Kimberly Sesperez; Eitan Ben-Sefer; David Arpon; Kristine McGrath; Lana McClements; Carmine Gentile
Journal:  Cells       Date:  2021-04-14       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.